Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 8/2023

17-03-2023 | Human Papillomavirus | Invited Review Article

Association between human papillomavirus and oral cancer: a literature review

Author: Hideo Shigeishi

Published in: International Journal of Clinical Oncology | Issue 8/2023

Login to get access

Abstract

HPV plays a vital role in the development of cervical cancers and oropharyngeal cancers, but it is controversial whether HPV is involved in oral cancer development and to what extent. In this review, the clinical characteristics, diagnosis, treatment, and prognosis of HPV-positive oral cancers are summarized, and the mechanisms of HPV-related oral cancer development are discussed. HPV DNA positivity rates are 20–30% in oral squamous cell carcinoma (OSCC), and HPV16 is the most common high-risk HPV. E6/E7 mRNA positivity rates are 2–6% in OSCC. Detection of both high-risk HPV DNA and E6/E7 mRNA is recommended to determine the presence of active HPV, in agreement with high-risk HPV infection in OSCC. Surgical treatment is the first-line therapy for HPV-positive and -negative oral cancer, but there is no unified view about the prognosis of HPV-positive OSCC patients. HPV16 may play a vital role in malignant transformation in oral epithelial dysplasia, and a model of synergistic carcinogenic impact of HPV and tobacco smoking is predicted. Additionally, it is hypothesized that there are different HPV-associated oral cancers, such as integrated HPV DNA-positive OSCC with stable E6/E7 expression and episomal HPV DNA-positive OSCC. In summary, the role of HPV in oral carcinogenesis seems to be limited because of the low E6/E7 positivity in OSCCs; however, episomal HPV DNA may play a vital role in the malignant transformation of HPV-positive oral premalignant lesions. Further investigation is required to promote new insights into the role of episomal HPV DNA in oral carcinogenesis.
Literature
1.
Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424PubMed
2.
3.
Hussein AA, Helder MN, de Visscher JG et al (2017) Global incidence of oral and oropharynx cancer in patients younger than 45 years versus older patients: a systematic review. Eur J Cancer 82:115–127PubMed
4.
5.
Kawakita D, Oze I, Iwasaki S et al (2022) Trends in the incidence of head and neck cancer by subsite between 1993 and 2015 in Japan. Cancer Med 11:1553–1560PubMedPubMedCentral
6.
Morikawa T, Futoo E, Funakoshi A et al (2016) Clinical statistical study of oral cancer in young patients during 25 years in our department (in Japanese). Jpn J Oral Maxillofac Surg 62:144–150
7.
Gholizadeh P, Eslami H, Yousefi M et al (2016) Role of oral microbiome on oral cancers, a review. Biomed Pharmacother 84:552–558PubMed
8.
Foy JP, Bertolus C, Boutolleau D et al (2020) Arguments to support a viral origin of oral squamous cell carcinoma in non-smoker and non-drinker patients. Front Oncol 10:822PubMedPubMedCentral
9.
Doorbar J, Quint W, Banks L et al (2012) The biology and life-cycle of human papillomaviruses. Vaccine 30(Suppl 5):F55-70PubMed
10.
Gillison ML, Broutian T, Pickard RKL et al (2012) Prevalence of oral HPV infection in the United States, 2009–2010. JAMA 307:693–703PubMedPubMedCentral
11.
D’Souza G, Cullen K, Bowie J et al (2014) Differences in oral sexual behaviors by gender, age, and race explain observed differences in prevalence of oral human papillomavirus infection. PLoS One 9:e86023PubMedPubMedCentral
12.
Giraldi L, Collatuzzo G, Hashim D et al (2021) Infection with human papilloma virus (HPV) and risk of subsites within the oral cancer. Cancer Epidemiol 75:102020PubMed
13.
Ndiaye C, Mena M, Alemany L et al (2014) HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol 15:1319–1331PubMed
14.
Kansy K, Thiele O, Freier K (2014) The role of human papillomavirus in oral squamous cell carcinoma: myth and reality. Oral Maxillofac Surg 18:165–172PubMed
15.
Li H, Park HS, Osborn HA et al (2018) Sex differences in patients with high risk HPV-associated and HPV negative oropharyngeal and oral cavity squamous cell carcinomas. Cancers Head Neck 3:4PubMedPubMedCentral
16.
Lingen MW, Xiao W, Schmitt A et al (2013) Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas. Oral Oncol 49:1–8PubMed
17.
Nauta IH, Heideman DAM, Brink A et al (2021) The unveiled reality of human papillomavirus as risk factor for oral cavity squamous cell carcinoma. Int J Cancer 149:420–430PubMedPubMedCentral
18.
19.
Rooper LM, Windon MJ, Hernandez T et al (2020) HPV-positive squamous cell carcinoma of the larynx, oral cavity, and hypopharynx: clinicopathologic characterization with recognition of a novel warty variant. Am J Surg Pathol 44:691–702PubMedPubMedCentral
20.
Yilmaz E, Ozbun MA, Gan GN et al (2021) Molecular and immune signature of HPV-positive oral cavity squamous cell carcinoma. Oral Oncol 116:105175PubMedPubMedCentral
21.
Gillison ML, Akagi K, Xiao W et al (2019) Human papillomavirus and the landscape of secondary genetic alterations in oral cancers. Genome Res 29:1–17PubMedPubMedCentral
22.
Durzynska J, Lesniewicz K, Poreba E (2017) Human papillomaviruses in epigenetic regulations. Mutat Res Rev Mutat Res 772:36–50PubMed
23.
van Kempen PM, Noorlag R, Braunius WW et al (2014) Differences in methylation profiles between HPV-positive and HPV-negative oropharynx squamous cell carcinoma: a systematic review. Epigenetics 9:194–203PubMed
24.
Reis RSD, Santos JAD, Abreu PM et al (2020) Hypermethylation status of DAPK, MGMT and RUNX3 in HPV negative oral and oropharyngeal squamous cell carcinoma. Genet Mol Biol 43:e20190334PubMedPubMedCentral
25.
Prawdzic Seńkowska A, Kiczmer P et al (2019) Impact of HPV infection on gene expression and methylation in oral cancer patients. J Med Microbiol 68:440–445PubMed
26.
Worsham MJ, Chen KM, Ghanem T et al (2013) Epigenetic modulation of signal transduction pathways in HPV-associated HNSCC. Otolaryngol Head Neck Surg 149:409–416PubMedPubMedCentral
27.
Lechner M, Liu J, Masterson L et al (2022) HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol 19:306–327PubMedPubMedCentral
28.
Japan Society of Clinical Oncology (2019) Clinical practice guidelines. jsco-cpg.jp.
29.
Elango KJ, Suresh A, Erode EM et al (2011) Role of human papilloma virus in oral tongue squamous cell carcinoma. Asian Pac J Cancer Prev 12:889–896PubMed
30.
Komolmalai N, Pongsiriwet S, Lertprasertsuke N et al (2020) Human papillomavirus 16 and 18 infection in oral cancer in Thailand: a multicenter study. Asian Pac J Cancer Prev 21:3349–3355PubMedPubMedCentral
31.
Isayeva T, Xu J, Ragin C et al (2015) The protective effect of p16(INK4a) in oral cavity carcinomas: p16(Ink4A) dampens tumor invasion-integrated analysis of expression and kinomics pathways. Mod Pathol 28:631–653PubMed
32.
Maeda K, Suzuki T, Ooyama Y et al (2010) Colorimetric analysis of unstained lesions surrounding oral squamous cell carcinomas and oral potentially malignant disorders using iodine. Int J Oral Maxillofac Surg 39:486–492PubMed
33.
Ansarin M, Bruschini R, Navach V et al (2019) Classification of GLOSSECTOMIES: proposal for tongue cancer resections. Head Neck 41:821–827PubMedPubMedCentral
34.
Yoshino T, Hasegawa Y, Takahashi S et al (2013) Platinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: results of a phase II trial. Jpn J Clin Oncol 43:524–531PubMedPubMedCentral
35.
Motai R, Sawabe M, Kadowaki S et al (2021) Clinical impact of weekly paclitaxel plus cetuximab is comparable to the EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma. Int J Clin Oncol 26:1188–1195PubMed
36.
Chen L, Mo DC, Hu M et al (2022) PD-1/PD-L1 inhibitor monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a meta-analysis. Am J Otolaryngol 43:103324PubMed
37.
Ferris RL, Blumenschen G, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856–1867PubMedPubMedCentral
38.
39.
Quayle SN, Girgis N, Thapa DR et al (2020) CUE-101, a novel E7-pHLA-IL2-Fc fusion protein, enhances tumor antigen-specific T-cell activation for the treatment of HPV16-driven malignancies. Clin Cancer Res 26:1953–1964PubMed
40.
Nagarsheth NB, Norberg SM, Sinkoe AL et al (2021) TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nat Med 27:419–425PubMedPubMedCentral
41.
Sugiyama M, Bhawal UK, Kawamura M et al (2007) Human papillomavirus-16 in oral squamous cell carcinoma: clinical correlates and 5-year survival. Br J Oral Maxillofac Surg 45:116–122PubMed
42.
Pérez-Islas E, García-Carrancá A, Acosta-Gio E et al (2022) Prognostic importance of DNA from human papillomavirus in patients with oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal 27:e150–e158PubMedPubMedCentral
43.
Christianto S, Li KY, Huang TH et al (2022) The prognostic value of human papilloma virus infection in oral cavity squamous cell carcinoma: a meta-analysis. Laryngoscope S132:1760–1770
44.
Nulton TJ, Kim NK, DiNardo LJ et al (2018) Patients with integrated HPV16 in head and neck cancer show poor survival. Oral Oncol 80:52–55PubMedPubMedCentral
45.
Shigeishi H, Sugiyama M (2016) Risk factors for oral human papillomavirus infection in healthy individuals: a systematic review and meta-analysis. J Clin Med Res 8:721–729PubMedPubMedCentral
46.
Holway GV, Hernandez SM (2018) Oral sex and condom use in a U.S. national sample of adolescents and young adults. J Adolesc Health 62:402–410PubMed
47.
Hanley SJ, Yoshioka E, Ito Y et al (2015) HPV vaccination crisis in Japan. Lancet 385:2571PubMed
48.
Barbour SE, Nakashima K, Zhang JB et al (1997) Tobacco and smoking: environmental factors that modify the host response (immune system) and have an impact on periodontal health. Crit Rev Oral Biol Med 8:437–460PubMed
49.
Yanagita M, Kobayashi R, Kojima Y et al (2012) Nicotine modulates the immunological function of dendritic cells through peroxisome proliferator-activated receptor-γ upregulation. Cell Immunol 274:26–33PubMed
50.
Dalla Torre D, Burtscher D, Sölder E et al (2019) The correlation between the quality of oral hygiene and oral HPV infection in adults: a prospective cross-sectional study. Clin Oral Investig 23:179–185PubMed
51.
Toyama K, Maeda H, Sugita Y et al (2008) A research of the state of oral hygiene, lifestyle and human papillomavirus premlence among senior high school students (in Japanese). Tokai J School Health 32:3–12
52.
Shigeishi H, Murodumi H, Ohta K et al (2021) Detection of HPV16 E6 DNA in periodontal pockets of middle-aged and older people. Oral Sci Int 18:50–55
53.
Ortiz AP, González D, Vivaldi-Oliver J et al (2018) Periodontitis and oral human papillomavirus infection among Hispanic adults. Papillomavirus Res 5:128–133PubMedPubMedCentral
54.
Shigeishi H, Sugiyama M, Ohta K (2021) Relationship between the prevalence of oral human papillomavirus DNA and periodontal disease (review). Biomed Rep 14:40PubMedPubMedCentral
55.
Saini R, Osman NB, Ismail M et al (2011) Association of human papillomavirus with denture wearing. J Investig Clin Dent 2:241–247PubMed
56.
Nishimura Y, Maeda H, Hattori M et al (2004) Human papillomavirus infection in the oral cavity of denture wearers (in Japanese). Nihon Hotetsu Shika Gakkai Zasshi 48:713–722PubMed
57.
Nascimento ACDS, Nocetti MC, Lugo LZA et al (2019) Oncogenic high-risk human papillomavirus in patients with full denture. Braz Oral Res 33:e091PubMed
58.
Pindborg JJ, Reichart PA, Smith CJ, et al. (1997) Histological typing of cancer and precancer of the oral mucosa, 2nd edn. World Health Organization International Classification of Tumours. Springer Verlag, Berlin, p 21–31
59.
Lerman MA, Almazrooa S, Lindeman N et al (2017) HPV-16 in a distinct subset of oral epithelial dysplasia. Mod Pathol 30:1646–1654PubMed
60.
Odell E, Kujan O, Warnakulasuriya S et al (2021) Oral epithelial dysplasia: recognition, grading and clinical significance. Oral Dis 27:1947–1976PubMed
61.
Syrjänen S, Lodi G, von Bültzingslöwen I et al (2011) Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: a systematic review. Oral Dis 17(Suppl 1):58–72PubMed
62.
Khanal S, Trainor PJ, Zahin M et al (2017) Histologic variation in high grade oral epithelial dysplasia when associated with high-risk human papillomavirus. Oral Surg Oral Med Oral Pathol Oral Radiol 123:566–585PubMed
63.
Sugiyama M, Bhawal UK, Dohmen T et al (2003) Detection of human papillomavirus-16 and HPV-18 DNA in normal, dysplastic, and malignant oral epithelium. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95:594–600PubMed
64.
Wei L, Griego AM, Chu M et al (2014) Tobacco exposure results in increased E6 and E7 oncogene expression, DNA damage and mutation rates in cells maintaining episomal human papillomavirus 16 genomes. Carcinogenesis 35:2373–2381PubMedPubMedCentral
65.
Su SC, Chang LC, Huang HD et al (2021) Oral microbial dysbiosis and its performance in predicting oral cancer. Carcinogenesis 42:127–135PubMed
66.
67.
Olthof NC, Speel EJ, Kolligs J et al (2014) Comprehensive analysis of HPV16 integration in OSCC reveals no significant impact of physical status on viral oncogene and virally disrupted human gene expression. PLoS One 9:e88718PubMedPubMedCentral
68.
Olthof NC, Huebbers CU, Kolligs J et al (2015) Viral load, gene expression and mapping of viral integration sites in HPV16-associated HNSCC cell lines. Int J Cancer 136:E207–E218PubMed
69.
Gray E, Pett MR, Ward D et al (2010) In vitro progression of human papillomavirus 16 episome-associated cervical neoplasia displays fundamental similarities to integrant-associated carcinogenesis. Cancer Res 70:4081–4091PubMedPubMedCentral
Metadata
Title
Association between human papillomavirus and oral cancer: a literature review
Author
Hideo Shigeishi
Publication date
17-03-2023
Publisher
Springer Nature Singapore
Published in
International Journal of Clinical Oncology / Issue 8/2023
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-023-02327-9

Other articles of this Issue 8/2023

International Journal of Clinical Oncology 8/2023 Go to the issue

Review Article

Opioids for the management of dyspnea in cancer patients: a systematic review and meta-analysis

Original Article

The prognostic significance of the clinical T stage and Grade Group in patients with locally advanced prostate cancer treated via high-dose-rate brachytherapy and external beam radiation

Original Article

Definitive S-1/mitomycin-C chemoradiotherapy for stage II/III anal canal squamous cell carcinoma: a phase I/II dose-finding and single-arm confirmatory study (JCOG0903)

Original Article

Impact of prior bevacizumab therapy on the incidence of ramucirumab-induced proteinuria in colorectal cancer: a multi-institutional cohort study

Invited Review Article

Papillomaviruses and cancer: commonalities and differences in HPV carcinogenesis at different sites of the body

Invited Review Article

Characteristics of anal canal squamous cell carcinoma as an HPV-associated cancer in Japan
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits